Raoul S. Concepcion, MD, FACS, Urology Associates P.C., Nashville, Tennessee, discusses if there are molecular markers to guide appropriate therapy in treating metastatic castration resistant prostate cancer patients.

Interview produced by Prostatepedia

Keywords: AR-V7, Radium-223, androgen receptor, enzalutamide, abiraterone, metastatic castration resistant prostate cancer